Supplementary Table 1. Hazard ratio (95% confidence interval) of the primary composite outcome and secondary outcomes reported in the cardiovascular outcome trials

CVOT	LEADER	ELIXA	SUSTAIN-6	EXSCEL	HARMONY	REWIND	PIONEER-6
GLP-1R agonist	Liraglutide [12]	Lixisenatide [13]	Semaglutide sc [14]	Exenatide [15]	Albiglutide [16]	Dulaglutide [17]	Semaglutide oral [18]
Composite MACE[a]	0.87 (0.78–0.97)	1.02 (0.89–1.17)	0.74 (0.58–0.95)	0.91 (0.83– 1.00)	0.78 (0.68–0.90)	0.88 (0.79–0.99)	0.79 (0.57–1.11)
CV death	0.78 (0.66–0.93)	0.98 (0.87–1.22)	0.98 (0.65–1.48)	0.88 (0.76–1.02)	0.93 (0.73–1.19)	0.91 (0.78–1.06)	0.49 (0.27–0.92)
Nonfatal MI	0.88 (0.75–1.03)	1.03 (0.87–1.22)[b]	0.74 (0.51–1.08)	0.97 (0.85–1.10)[b]	0.75 (0.61–0.90)[b]	0.96 (0.79–1.16)	1.18 (0.73–1.90)
Hospitalization HF	0.87 (0.73–1.05)	0.96 (0.75–1.23)	1.11 (0.77–1.61)	0.94 (0.78–1.13)	0.85 (0.70–1.04)[c]	0.93 (0.77–1.12)	0.86 (0.48–1.55)
Stroke	0.89 (0.72–1.11)	1.12 (0.79–1.58)	0.61 (0.38–0.99)	0.85 (0.70–1.03)[b]	0.86 (0.66–1.14)[b]	0.76 (0.61–0.95)	0.74 (0.35–1.57)
All-cause mortality	0.85 (0.74–0.97)	0.94 (0.78–1.13)	1.05 (0.74–1.5)	0.86 (0.77–0.97)	0.95 (0.79–1.16)	0.9 (0.80–1.01)	0.51 (0.31–0.84)

CVOT, cardiovascular outcome trial; GLP-1R, glucagon-like peptide 1 receptor; sc, subcutaneous; MACE, major adverse cardiac event; CV, cardiovascular; MI, myocardial infarction; HF, heart failure.

[a]In LEADER, SUSTAIN-6, EXSCEL, HARMONY, REWIND and PIONEER-6 trials composite MACE was three-component outcome defined by the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. In ELIXA trial, primary end point (MACE plus) was the first occurrence of death from cardiovascular causes, nonfatal stroke, nonfatal myocardial infarction or unstable angina, [b]Fatal and nonfatal, [c]Composite of death from cardiovascular causes or hospital admission for heart failure.